KG
PTGX icon

Kilter Group’s Protagonist Therapeutics PTGX Stock Holding History

Kilter Group’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$491 Hold
4
– – ﹤0.01% 1386
2026
Q1 		$422 Hold
4
– – ﹤0.01% 1385
2025
Q4 		$350 Hold
4
– – ﹤0.01% 1233
2025
Q3 		$266 Hold
4
– – ﹤0.01% 1142
2025
Q2 		$222 Buy
+4
New +$192 ﹤0.01% 1093

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Kilter Group's PTGX Position: Q2 2026 in Review

Kilter Group held its Protagonist Therapeutics (PTGX) position steady in Q2 2026 at 4 shares worth $491. The position accounts for ﹤0.01% of the portfolio, ranked #1386.

Kilter Group first reported a position in PTGX in Q2 2025 and has held it in 5 quarters since. 343 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

  • Kilter Group held 4 shares of Protagonist Therapeutics worth $491 as of Q2 2026.
  • Kilter Group left its Protagonist Therapeutics share count unchanged in Q2 2026.
  • Protagonist Therapeutics made up ﹤0.01% of Kilter Group's portfolio in Q2 2026, its #1386 holding.
  • Kilter Group first reported a position in Protagonist Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • 343 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Kilter Group's 13F filing for Q2 2026, filed 11 Aug 2026.